Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kirstine Ullitz Færch"'
Autor:
Mikkel Christensen, Cille Bülow, Josefine Dalgaard Scheel Vandel Noergaard, Caroline Pontoppidan, Janne Unkerskov, Jonatan Kornholt, Kirstine Ullitz Færch, Karl Sebastian Johansson
Publikováno v:
Basicclinical pharmacologytoxicologyREFERENCES. 129(3)
Discrepancies between registered prescriptions and patients' actual use of medications are described as frequent and often resulting in adverse medication events. We aimed to assess the extent of and causes behind discrepancies between medications li
Autor:
Cille Bülow, Helle Byg Armandi, Christine Flagstad Bech, Charlotte Treldal, Kirstine Ullitz Faerch, Jon Trærup Andersen
Publikováno v:
The Senior care pharmacist. 34(5)
Discrepancies between electronic prescribing systems and patients' actual use of medicines can result in adverse events and medication errors and have serious consequences for the patients. The discrepancies can be identified when performing a thorou
Autor:
Lars-Erik Broksoe Kyhl, Frank Larsen, Johan Areberg, Birgitte Soegaard, Kirstine Ullitz Faerch, Shen Li
Publikováno v:
British Journal of Clinical Pharmacology. 81:290-300
Aims The aims of this study were to develop a population pharmacokinetic (PK) model to describe the PK of nalmefene in healthy subjects and to relate the exposure of nalmefene to the μ-opioid receptor occupancy by simulations in the target populatio
Autor:
Hanne Rolighed Christensen, Birgitte Nybo Jensen, Jesper Sonne, Mikkel B. Christensen, Kirstine Ullitz Faerch, Helle Byg Armandi, Cille Bülow
Publikováno v:
Basicclinical pharmacologytoxicology. 122(2)
In some hospitals, clinical pharmacists review the medication to find drug-related problems (DRPs) in acutely admitted patients. We aimed to identify the nature of identified DRPs and investigate factors of potential importance for the clinical imple
Autor:
Lars-Erik Broksoe, Kyhl, Shen, Li, Kirstine Ullitz, Faerch, Birgitte, Soegaard, Frank, Larsen, Johan, Areberg
Publikováno v:
British journal of clinical pharmacology. 81(2)
The aims of this study were to develop a population pharmacokinetic (PK) model to describe the PK of nalmefene in healthy subjects and to relate the exposure of nalmefene to the μ-opioid receptor occupancy by simulations in the target population.Dat